FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Another Rock Island County Sheriff’s Office deputy said he intends to run for sheriff in 2026. Timothy Gillette, a 28-year ...

Despite the many warnings by law enforcement — reinforced by this newspaper — to be wary of anyone purporting to act in your best interests, egregious examples of violations of that trust continue ...

Around 5:30 p.m., troopers were sent to a report of a single motorcycle crash where Megan Bouchard, 25, the rider, was on a ...